Teleflex Incorporated TFX recently unveiled the UroLift Advanced Tissue Control (ATC) System and the UroLift 2 System together with real-world data presentations at the American Urological Association ...

Teleflex TFX recently announced the upcoming full market release of the Advanced Tissue Control (“ATC”) feature on its unified UroLift 2 System — a platformdesigned for the treatment of benign ...

The US Food and Drug Administration (FDA) today authorized the marketing of the UroLift system, the first permanent implant to relieve low or blocked urine flow in men aged 50 years and older with an ...

More than 50% of men over the age of 50 suffer from benign prostatic hyperplasia, also known as an enlarged prostate. While BPH is common for older men, causing the frequent urge to urinate — ...

The committee concluded that UroLift is clinically effective, with sustained relief of lower urinary tract symptoms up to 5 years after treatment. It is implanted using a minimally invasive procedure.

FDA Approves UroLift System for Enlarged Prostate The FDA has authorized the marketing of NeoTract Inc.'s UroLift system, a permanent implant to relieve low or blocked urine flow in men with an ...

Enid (Okla.) Urology Associates treated its 350th patient with the UroLift System. Here's what you should know: 1. NeoTract's UroLift System treats symptoms associated with benign prostatic ...

NICE commissioned an external assessment centre (EAC) to review the evidence submitted by the company. This section summarises that review. Full details of all the evidence are in the project ...